Phase 4 N=58 Randomized Double-blind Treatment

Comparison of Time to Extubation Using Sugammadex or Neostigmine

Neuromuscular Blockade · Chronic Obstructive Pulmonary Disease

Bottom Line

View on ClinicalTrials.gov: NCT04606901 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2024

Primary outcome: Primary: Number of Minutes to Return of Baseline Muscle Tone — 3.9; 12.9 minutes

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: neostigmine/glycopyrrolate (Drug); sugammadex (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Temple University
Primary completion: Jul 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Minutes to Return of Baseline Muscle Tone	3.9; 12.9	—
SECONDARY Number of Minutes to Extubation	11.9; 17.7	—

Summary

A prospective blinded randomized clinical trial to compare time to extubation using Sugammadex versus Neostigmine/glycopyrrolate as reversal agents after use of neuromuscular blockade agents in an outpatient bronchoscopy suite.

Eligibility Criteria

Inclusion Criteria

has diagnosis of COPD or ILD
ASA 3 or 4
procedure requires general anesthesia in the outpatient bronchoscopy suite
glomerular filtration rate > 30 ml/min

Exclusion Criteria

pregnant women
prisoners
those unable to consent for themselves
procedures not requiring general anesthesia
ASA 1 or 2

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04606901). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.